Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Burkitt Lymphoma 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Biphenotypic, Acute 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myeloid, Accelerated Phase 1Down Syndrome 1Blast Crisis 1

Interventions

Vincristine 4Dexamethasone 4merphos 3dexamethasone acetate 3dexamethasone 21-phosphate 3blinatumomab 3azathiopurine 3auricularum 3Methotrexate 3Mercaptopurine 3Doxorubicin 3Cytarabine 3Cyclophosphamide 3Calcium Dobesilate 3prednylidene 2pegaspargase 2deltacortene 2Thioguanine 2Prednisone 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Leucovorin 2venetoclax 1ofatumumab 1asparaginase erwinia chrysanthemi recombinant 1Spinal Puncture 1Specimen Handling 1Rituximab 1Radiotherapy 1Radiation 1Prednisolone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma × N,N-dicyclohexyl-isoborneol-10-sulfonamide × 30 days × Clear all
NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
6,720 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT02877303 2026-05-20

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
80 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡